For doctors
Request a partnership call.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
Peptides · Tissue repair (under FDA review)
BPC-157
Body Protection Compound — under FDA review for 503A access.
What it does
What BPC-157 is and why doctors prescribe it.
BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide derived from a sequence found in human gastric juice. Research interest centers on tendon, ligament, and gut-tissue repair. As of 2026, it sits under FDA review for movement from Category 2 to a 503A-permissible status, with a decision targeted for July 2026.
How it works
Mechanism in plain English.
Mechanistic studies suggest BPC-157 modulates angiogenesis (VEGF-pathway effects), nitric oxide signaling, growth factor receptor expression (e.g., VEGFR2), and gastrointestinal mucosal protection. Effects on tendon/ligament repair have been demonstrated in animal models; human clinical evidence is limited and much of the published literature is preclinical.
How long it's been studied
Research history.
BPC-157 was first characterized in the 1990s by researchers in Croatia and Yugoslavia. The peer-reviewed body of work is largely preclinical (rodent models) with some early-stage human investigation. Cannot currently be compounded under 503A; this is the regulatory gap the proposed FDA review may address.
Dosing
Clinical context for the prescribing doctor.
Pending regulatory clarity. Until BPC-157 moves to 503A-permissible status, RonanRx cannot compound it. Once the FDA makes its determination, doctor-prescribed dosing protocols will be informed by available clinical evidence and the supervising pharmacist's judgment.
This page is informational, not a dispensing aid. BPC-157 is dispensed only on a patient-specific prescription written by a licensed doctor for an identified patient. Compounded drugs are not FDA-approved and should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
How to access BPC-157 through RonanRx
Three paths.
BPC-157 is currently in Category 2 and not available for 503A compounding. RonanRx is tracking the FDA review and will notify partner clinics when the decision allows compounding access.
Patient with a doctor
Sign up to receive your prescription.
If your doctor has already prescribed BPC-157, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
Patient without a doctor
Get referred by a partner clinic.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. Read how the referral process works and how to find a partner clinic in your state.